CoronaryAtlas logo
CoronaryAtlas
Plasminogen
Pathway / Coagulation & thrombus formation

Plasminogen

PLGprotein

Plasminogen activation to plasmin drives fibrin degradation and thrombus resolution in coronary occlusion.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleFibrinolytic pathway activation; thrombus lysis marker.
Also acts inThromboxane / COX-1, Myocardial injury, Platelet activation
Druggability
DruggableYes
Known drugs / candidates9
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000122194

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
50
A — assay feasibility
84
E — evidence strength
35
T1DI (composite)
10
Specificity differential (R−C)-35
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 1
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 2/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 15 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Platelet-poor plasma
Collection tube
Sodium citrate 3.2% (light blue-top)
Method / principle
Chromogenic activity assay
Reagent / substrate
Streptokinase activation + chromogenic plasmin substrate (e.g. S-2251), read 405 nm
Platform
Coagulation analyzer
Turnaround · availability
Send-out · Specialized lab

Human genetic evidence

0.561
Open Targets association (myocardial_infarction)
4
GWAS associations
Traits: myocardial infarction

Literature evidence(16)

Clinical trials(1)